• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Evernorth Launches New Benefit Option That Drives Lower Net Cost for Weight Loss Medicines and Limits Patient Cost to No More Than $200 Per Month

    5/21/25 4:30:00 PM ET
    $CI
    Medical Specialities
    Health Care
    Get the next $CI alert in real time by email
    • Patients can save as much as $3600 per year versus direct-to-consumer manufacturer programs, and out of pocket cost applies to their annual deductible
    • New offering helps employers meet growing demand for FDA-approved weight loss medications at a lower net cost per prescription while ensuring clinical safety for patients

    ST LOUIS, May 21, 2025  /PRNewswire/ -- Evernorth, the health services division of The Cigna Group (NYSE:CI) announced a first-of-its-kind pharmacy benefit offering that make weight loss medications WEGOVY® and ZEPBOUND® more available to patients. Through direct negotiations with the medications' manufacturers, Evernorth has ensured that patients' monthly cost will not exceed $200.

    Evernorth Health Services (PRNewsfoto/Evernorth Health Services)

    "We are reimagining pharmacy benefits to reduce costs and better serve patients," said Adam Kautzner, Pharm D, President of Evernorth Care Management and Express Scripts. "This is what Express Scripts does better than anyone: save Americans money on their prescriptions while helping them achieve their health goals." 

    This initiative fills a critical need in the market by offering savings, choice and predictability to both patients and health plan sponsors.

    Benefits for Patients:

    • Lower Monthly Copays than Cash Programs: The monthly copay for GLP-1 weight loss medicines will be limited to no more than $200, which will have the added benefit of counting towards the patient's annual deductible.
    • Meaningful Savings: Patients can save as much as $3,600 per year compared to buying these medications directly from manufacturers or through consumer programs.
    • Enhanced Safety and Efficacy: By accessing WEGOVY® or ZEPBOUND® through Evernorth's pharmacy benefit, patients will benefit from FDA-approved medications and Express Scripts' robust safety checks designed to reduce negative or adverse drug interactions.
    • Simplified Approval and Access: The prior authorization processes accompanying the new offering will be simplified and automated for faster access.
    • Choice of Pharmacies: Patients can select from a broad network of local retail pharmacies or home delivery through Evernorth's EnGuide Pharmacy, staffed by clinicians with specialized knowledge in GLP-1s for enhanced support.

    Benefits for Employers & Other Health Plan Sponsors:

    • Significant Cost Reduction: Health plan sponsors will see a significant reduction in the net cost per prescription of GLP-1 medications.
    • Offering Patient Options: Health plan sponsors can ensure that patients have access to the medication that works best for them, without compromising affordability or clinical safety.

    "As advocates for the millions of people we serve, we drive lower medication costs through negotiations with the pharmaceutical manufacturers, and we're making it easier than ever for health plan sponsors to cover GLP-1s for weight loss," said Harold Carter, PharmD, senior vice president of trade relations at Express Scripts. "This is how we deliver on our promise to put patients first - by making innovative medicines more accessible, at a lower cost, while providing patients and physicians choices in this fast-evolving market."

    Evernorth has the most extensive suite of GLP-1 solutions available with this new addition, which also includes:

    • EncircleRx, a financial model with more than 9 million enrolled lives that has saved health plans $200 million dollars since 2024.
    • EnReachRx, a high-touch patient support clinical model for dispensing GLP-1 prescription medications.

    About Evernorth Health Services

    Evernorth Health Services creates pharmacy, care, and benefits solutions to improve health and increase vitality. We relentlessly innovate to make the prediction, prevention, and treatment of illness and disease more accessible to millions of people. Evernorth capabilities are powered by our businesses, including Express Scripts, Express Scripts® Pharmacy, Accredo, eviCore, and MDLIVE, along with holistic Evernorth platforms and solutions that move people and organizations forward. All Evernorth solutions are serviced and provided by or through operating affiliates of Evernorth Health, a wholly owned subsidiary of The Cigna Group (NYSE:CI), or third-party partners. Learn more at evernorth.com.

    Media Contact:

    Justine Sessions

    [email protected]

    860-810-6523

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/evernorth-launches-new-benefit-option-that-drives-lower-net-cost-for-weight-loss-medicines-and-limits-patient-cost-to-no-more-than-200-per-month-302462363.html

    SOURCE Evernorth

    Get the next $CI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CI

    DatePrice TargetRatingAnalyst
    2/6/2025$323.00Outperform → Mkt Perform
    Bernstein
    6/26/2024$400.00Overweight
    Piper Sandler
    5/30/2024$388.00Outperform
    Robert W. Baird
    3/6/2024$393.00Overweight
    Barclays
    2/5/2024$334.00 → $372.00Neutral → Overweight
    Cantor Fitzgerald
    2/5/2024$327.00 → $354.00Sector Perform → Outperform
    RBC Capital Mkts
    2/1/2024$355.00 → $370.00Hold → Buy
    Deutsche Bank
    1/4/2024$330.00 → $372.00Mkt Perform → Outperform
    Bernstein
    More analyst ratings

    $CI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • The Cigna Group downgraded by Bernstein with a new price target

      Bernstein downgraded The Cigna Group from Outperform to Mkt Perform and set a new price target of $323.00

      2/6/25 7:05:01 AM ET
      $CI
      Medical Specialities
      Health Care
    • Piper Sandler initiated coverage on The Cigna Group with a new price target

      Piper Sandler initiated coverage of The Cigna Group with a rating of Overweight and set a new price target of $400.00

      6/26/24 7:28:18 AM ET
      $CI
      Medical Specialities
      Health Care
    • Robert W. Baird initiated coverage on The Cigna Group with a new price target

      Robert W. Baird initiated coverage of The Cigna Group with a rating of Outperform and set a new price target of $388.00

      5/30/24 7:35:19 AM ET
      $CI
      Medical Specialities
      Health Care

    $CI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AI Healthcare Funding Surges as Real-World Rollouts Hit Pharmacies, Hospitals, and Providers

      Equity Insider News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 17, 2025 /PRNewswire/ -- Venture Capital continues to flow in bunches into the AI in healthcare sector, with AI companies capturing more than half of digital health funding in Q1. Investors are seeking novel opportunities that tap into this space, with private companies such as Ellipsis Health and Autonomize AI recently receiving $45M and $28M respectively for their innovations. For other investors seeking opportunities among publicly traded companies, there's been plenty of development to follow from innovators, including from Avant Technologies, Inc. (OTCQB:AVAI), IQVIA Holdings Inc. (NYSE:IQV), S

      6/17/25 10:17:00 AM ET
      $CI
      $IQV
      $RDNT
      $SOUN
      Medical Specialities
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Computer Software: Prepackaged Software
    • Cigna Healthcare Unveils Industry-Leading AI-Powered Digital Tools for a Simple and Reliable Customer Experience

      New features blend innovation, responsible AI, and human interactions to better support customers in their health care journeysAs new data show 4 out of 5 U.S. adults don't feel confident in their knowledge of health insurance benefits, new digital tools use clear, conversational language to boost understanding and help customers get more out of their coverageBLOOMFIELD, Conn., June 12, 2025 /PRNewswire/ -- Cigna Healthcare, the health benefits division of The Cigna Group (NYSE:CI), is introducing a series of new digital features to improve the customer experience during common health insurance interactions, such as checking benefits coverage, estimating costs and finding care. These enhance

      6/12/25 6:00:00 AM ET
      $CI
      Medical Specialities
      Health Care
    • New PPO Dental Plans More Competitive Against HMOs

      LOS ANGELES, June 11, 2025 /PRNewswire/ -- DentalInsurance.com, the leader in dental insurance comparison shopping, has broadened its inventory of PPO dental plans offering high maximum benefits. A maximum benefit is the annual cap on insurance company spending toward a consumer's covered dental care. PPO plans have a maximum benefit limit while HMO dental insurance doesn't. PPOs, however, have much wider dentist networks than most competing HMO plans. This helps consumers receive quality dental care from a trusted preferred dentist. By adding high maximum benefits, a new generation of PPO dental plans have become an even more attractive option for consumers.

      6/11/25 10:07:00 AM ET
      $CI
      $HUM
      $MET
      Medical Specialities
      Health Care
      Life Insurance
      Finance

    $CI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hennigan Michael J was granted 568 shares (SEC Form 4)

      4 - Cigna Group (0001739940) (Issuer)

      6/4/25 4:58:29 PM ET
      $CI
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Hennigan Michael J

      3 - Cigna Group (0001739940) (Issuer)

      6/3/25 5:04:45 PM ET
      $CI
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Kurian George

      4 - Cigna Group (0001739940) (Issuer)

      6/3/25 5:04:40 PM ET
      $CI
      Medical Specialities
      Health Care